<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1278701</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2023.1278701</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of <italic>Adenanthera pavonina</italic>-derived compounds against diabetes mellitus: insight into the phytochemical analysis and <italic>in silico</italic> assays</article-title>
<alt-title alt-title-type="left-running-head">Rahman et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2023.1278701">10.3389/fmolb.2023.1278701</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Rahman</surname>
<given-names>Md. Sojiur</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2508691/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Data curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Formal Analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing\x{2013}original draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Hosen</surname>
<given-names>Md. Eram</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2313326/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Data curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Formal Analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faruqe</surname>
<given-names>Md. Omar</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2282365/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Formal Analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Software/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khalekuzzaman</surname>
<given-names>Md.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Islam</surname>
<given-names>Md. Asadul</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Acharjee</surname>
<given-names>Uzzal Kumar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bin Jardan</surname>
<given-names>Yousef A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Project administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/Funding acquisition/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nafidi</surname>
<given-names>Hiba-Allah</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Project administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/Funding acquisition/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mekonnen</surname>
<given-names>Amare Bitew</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2283620/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Project administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/Funding acquisition/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Bourhia</surname>
<given-names>Mohammed</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/915935/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Project administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/Funding acquisition/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zaman</surname>
<given-names>Rashed</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/337917/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Formal Analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Project administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Professor Joarder DNA and Chromosome Research Laboratory</institution>, <institution>Department of Genetic Engineering and Biotechnology</institution>, <institution>University of Rajshahi</institution>, <addr-line>Rajshahi</addr-line>, <country>Bangladesh</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Computer Science and Engineering</institution>, <institution>University of Rajshahi</institution>, <addr-line>Rajshahi</addr-line>, <country>Bangladesh</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Pharmaceutics, College of Pharmacy, King Saud University</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Food Science</institution>, <institution>Faculty of Agricultural and Food Sciences</institution>, <institution>Laval University</institution>, <addr-line>Quebec City</addr-line>, <addr-line>QC</addr-line>, <country>Canada</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Biology</institution>, <institution>Bahir Dar University</institution>, <addr-line>Bahir Dar</addr-line>, <country>Ethiopia</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Laboratory of Biotechnology and Natural Resources Valorization, Faculty of Sciences, Ibn Zohr University</institution>, <addr-line>Agadir</addr-line>, <country>Morocco</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1590522/overview">Ilhami Gulcin</ext-link>, Atat&#xfc;rk University, T&#xfc;rkiye</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/763265/overview">Anupam Nath Jha</ext-link>, Tezpur University, India</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1837670/overview">Opeyemi Iwaloye</ext-link>, Federal University of Technology, Nigeria</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Rashed Zaman, <email>rashedzaman@ru.ac.bd</email>; Mohammed Bourhia, <email>bourhiamohammed@gmail.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>10</volume>
<elocation-id>1278701</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>08</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Rahman, Hosen, Faruqe, Khalekuzzaman, Islam, Acharjee, Bin Jardan, Nafidi, Mekonnen, Bourhia and Zaman.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Rahman, Hosen, Faruqe, Khalekuzzaman, Islam, Acharjee, Bin Jardan, Nafidi, Mekonnen, Bourhia and Zaman</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<italic>Adenanthera pavonina</italic> is a medicinal plant with numerous potential secondary metabolites showing a significant level of antidiabetic activity. The objective of the current study was to identify potential phytochemicals from the methanolic leaf extract of <italic>Adenanthera pavonina</italic> as therapeutic agents against diabetes mellitus using GC-MS and <italic>in silico</italic> methods. The GC-MS analysis of the leaf extract revealed a total of 17 phytochemicals. Molecular docking was performed using these phytochemicals, targeting the mutated insulin receptor tyrosine kinase (5hhw), which inhibits glucose uptake by cells. Diazoprogesterone (&#x2212;9.2&#xa0;kcal/mol), 2,4,4,7a-Tetramethyl-1-(3-oxobutyl)octahydro-1H-indene-2-carboxylic acid (&#x2212;6.9&#xa0;kcal/mol), and 2-Naphthalenemethanol, decahydro-.alpha.,.alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha.,8a.beta.)] (&#x2212;6.6&#xa0;kcal/mol) exhibited better binding with the target protein. The ADMET analysis was performed for the top three compounds with the best docking scores, which showed positive results with no observed toxicity in the AMES test. Furthermore, the molecular dynamics study confirmed the favorable binding of Diazoprogesterone, 2,4,4,7a-Tetramethyl-1-(3-oxobutyl)octahydro-1H-indene-2-carboxylic acid and 2-Naphthalenemethanol, decahydro-.alpha.,.alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha.,8a.beta.)] with the receptor throughout the 100&#xa0;ns simulation period.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FMOLB_fmolb-2023-1278701_wc_abs.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>
<italic>Adenanthera pavonina</italic>
</kwd>
<kwd>phytochemicals</kwd>
<kwd>diabetes mellitus</kwd>
<kwd>5hhw</kwd>
<kwd>molecular docking</kwd>
<kwd>molecular dynamics</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Biological Modeling and Simulation</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>1 Introduction</title>
<p>
<italic>Adenanthera pavonina</italic>, a member of the Fabaceae family, is a highly valued plant in traditional medicine due to its diverse medicinal properties. This plant species is known to be effective in treating various diseases, such as diabetes, lipid disorders, and diarrhea (<xref ref-type="bibr" rid="B28">Pandhare et al., 2012</xref>). The therapeutic potential of <italic>Adenanthera pavonina</italic> is attributed to its rich composition of phytochemicals, which includes steroids, glycosides, alkaloids, saponins, and polysaccharides (<xref ref-type="bibr" rid="B43">Wickramaratne et al., 2016</xref>). The plant extracts have been shown to exhibit a wide range of biological activities, including antidiabetic, antioxidant, anti-inflammatory and antimicrobial properties. Research on mice models has shown that <italic>A. pavonina</italic> leaf extract can effectively reduce the prevalence of diabetes mellitus (<xref ref-type="bibr" rid="B43">Wickramaratne et al., 2016</xref>).</p>
<p>Diabetes mellitus is one of the fastest-growing chronic metabolic disorders characterized by hyperglycemia (<xref ref-type="bibr" rid="B22">Karadag et al., 2018</xref>). In Bangladesh, India, and China, the number of patients suffering from diabetes mellitus type 2 (DMT2) has drastically increased (<xref ref-type="bibr" rid="B11">Goyal et al., 2020</xref>). Worldwide fast nutritional transitions, which involve altered eating habits, poor nutrition in early life and overnutrition in later life, can contribute to the DMT2 epidemic. In addition, Asians typically have a higher percentage of body fat mass, more abdominal obesity, and less muscle mass (<xref ref-type="bibr" rid="B15">Hills et al., 2018</xref>), which could account for their elevated susceptibility to DMT2. It has been also found that men are more prone to DMT2 than women (<xref ref-type="bibr" rid="B16">Iglay et al., 2016</xref>).</p>
<p>Insulin resistance and less insulin production are two key factors responsible for DMT2, which is characterized by abnormal metabolism of carbohydrates, proteins, and lipids by peripheral tissues (<xref ref-type="bibr" rid="B35">Saxena et al., 2019</xref>). DMT2 is far more prevalent than diabetes mellitus type 1 (DMT1). The primary cause of DMT2 is the increasing impairment in the ability of pancreatic beta-cells to secrete insulin, which typically occurs due to pre-existing insulin resistance in adipose tissue, liver, and skeletal muscle (<xref ref-type="bibr" rid="B26">Masini et al., 2017</xref>).</p>
<p>The insulin receptor (IR) is a tetrameric protein composed of two extracellular alpha and two transmembrane beta subunits (<xref ref-type="bibr" rid="B13">Hall et al., 2020</xref>). The tyrosine kinase beta subunit is activated through conformational changes induced by the binding of insulin to the alpha subunit of IR. Moreover, activated IR can phosphorylate and auto-phosphorylate intracellular substrates, both of which are necessary for initiating cellular responses to insulin (<xref ref-type="bibr" rid="B12">Haeusler et al., 2018</xref>). These actions activate downstream signaling molecules involved in the insulin-signaling pathway (<xref ref-type="bibr" rid="B4">Brierley et al., 2018</xref>). Impaired insulin signaling, including mutations in the insulin receptor tyrosine kinase (5hhw), is present in most diabetes mellitus patients. This insulin resistance contributes to hyperglycemia and other metabolic disorder (<xref ref-type="bibr" rid="B27">Nolan et al., 2019</xref>). Therefore, drugs that enhance insulin receptor tyrosine kinase activity might be helpful to deal with DMT2.</p>
<p>There are several medications to treat diabetes mellitus, such as insulin and metformin, which are costly and responsible for different types of side effects in the human body (<xref ref-type="bibr" rid="B3">Bao et al., 2021</xref>). However, natural plant-derived phytochemicals are relatively safe and less expensive. <italic>A. pavonina</italic> has been reported to possess bioactive substances that fight against DMT2 (<xref ref-type="bibr" rid="B28">Pandhare et al., 2012</xref>). Therefore, the information gathered from the molecular docking investigation of substances from <italic>A. pavonina</italic> with the 5hhw protein is crucial. The present study was conducted to identify potential activators of 5hhw and to report the interactions of phytochemicals with the target protein for further investigation.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<p>The overall workflow for identifying the potential activators of 5hhw protein is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Overall workflow to find out the potential phytochemicals.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g001.tif"/>
</fig>
<sec id="s2-1">
<title>2.1 Leaf extract preparation</title>
<p>The leaves of <italic>A. pavonina</italic> were first washed with distilled water to remove dust and then air-dried for 7&#xa0;days in a well-ventilated area. Next, the dried leaves were ground into a fine powder. A 5&#xa0;g powdered sample was extracted with 150&#xa0;mL of 100% methanol solvent to produce the crude extract containing a wide range of bioactive compounds. The extract was filtered using Whatman No. 4 filter paper, and the solvent was completely evaporated using a rotary evaporator to produce a dense residue. The completely evaporated extract was then weighed and stored at 4&#xb0;C.</p>
</sec>
<sec id="s2-2">
<title>2.2 GC-MS analysis</title>
<p>The phytochemicals present in the methanolic leaf extract of <italic>A. pavonina</italic> were detected through GC-MS (Shimadzu, Japan; Model GC&#x2013;MS QP 2020) analysis with an Electronic Ionization (EI) detector. A fused silica capillary column (SH-Rxi-5Sil MS 30m (L) X 0.25&#xa0;mm (ID), X 0.25&#xa0;um (DF)) was used at a temperature of 80.0&#xb0;C. The samples were taken in a fixed split mode at 220.00&#xb0;C. The oven was preheated at 80.0&#xb0;C for 2&#xa0;min, then 150.0&#xb0;C for 3&#xa0;min, and finally 280.0&#xb0;C for 5&#xa0;min. The ionization voltage was adjusted to 70&#xa0;eV and the electron multiplier was set to 450&#xa0;V. The unknown spectra of GC-MS were then compared to the spectra of existing chemicals housed in the NIST08s, NIST08 and NIST14 libraries. The names of the compounds and their concentrations were determined at different retention times (<xref ref-type="bibr" rid="B21">Kanthal et al., 2014</xref>). GC-MS Post Run software was used for data analysis.</p>
<p>Throughout this study, we bridge the gap between chemical composition and antidiabetic activity, starting with the identification of compounds through GC-MS and proceeding to the assessment of their potential interactions with 5hhw by molecular docking.</p>
</sec>
<sec id="s2-3">
<title>2.3 Molecular docking study</title>
<sec id="s2-3-1">
<title>2.3.1 Preparation of ligands</title>
<p>In the preparation of ligands, the structures of phytochemicals detected through the GC-MS technique from the methanolic leaf extract were retrieved from the PubChem database (<xref ref-type="bibr" rid="B5">Choudhary et al., 2019</xref>) in SDF format. Afterward, the Avogadro software was used to optimize the geometry of the phytochemicals (<xref ref-type="bibr" rid="B37">Snyder and Kucukkal, 2021</xref>).</p>
</sec>
<sec id="s2-3-2">
<title>2.3.2 Preparation of protein</title>
<p>The crystal structure of the mutated insulin receptor tyrosine kinase protein (PDB ID: 5hhw) was retrieved from the Protein Data Bank (<xref ref-type="bibr" rid="B38">Stauffer et al., 2016</xref>) in PDB format. Heteroatoms were then removed using Discovery Studio software, and the cleaned protein was minimized and its energy optimized using Swiss PDB viewer software (<xref ref-type="bibr" rid="B19">Jin et al., 2019</xref>).</p>
</sec>
<sec id="s2-3-3">
<title>2.3.3 Molecular docking</title>
<p>To investigate the interactions between the 5hhw protein and chemical compounds from <italic>A. pavonina</italic>, a molecular docking study was performed using the PyRx software with AutoDock Wizard (<xref ref-type="bibr" rid="B9">Dallakyan and Olson, 2015</xref>). The gasteiger charges for ligands CID: 104633 (0.002), CID: 536510 (&#x2212;0.999), CID: 6432456 (&#x2212;0.9997) and kollhman charges of protein (&#x2212;8.31) were added and then converted to PDBQT format. The center and grid box size of the docked complexes were set at X: &#x2212;14.5737&#xa0;&#xc5;, Y: &#x2212;15.6369&#xa0;&#xc5;, Z: 18.2605&#xa0;&#xc5; and X: 54.6511&#xa0;&#xc5;, Y: 55.6782&#xa0;&#xc5;, Z: 52.9565&#xa0;&#xc5;, respectively, and all the amino acid residues of 5hhw protein were considered for blind docking. The final docking calculation was performed using PyRx, generating a total of nine poses for docking, and the best compounds were selected based on the highest binding energy. The binding interactions were analyzed using Discovery Studio software (<xref ref-type="bibr" rid="B31">Riyaphan et al., 2021</xref>).</p>
</sec>
</sec>
<sec id="s2-4">
<title>2.4 ADMET analysis</title>
<p>Phytochemicals screened through molecular docking were analyzed for absorption, distribution, metabolism, excretion and toxicity (ADMET) to determine whether they possessed the anticipated features to be used as lead molecules. To analyze ADMET profiles and determine molecules&#x2019; correspondence to Lipinski&#x2019;s rule of five, the pkcsm (<xref ref-type="bibr" rid="B30">Pires et al., 2015</xref>) and SwissADME (<xref ref-type="bibr" rid="B7">Daina et al., 2017</xref>) web servers were used.</p>
</sec>
<sec id="s2-5">
<title>2.5 Molecular dynamics</title>
<p>Molecular dynamics simulations were carried out using YASARA (Yet Another Scientific Artificial Reality Application) dynamics software and the AMBER (Assisted Model Building with Energy Refinement) 14 force field (<xref ref-type="bibr" rid="B14">He et al., 2020</xref>). Initial cleanup and optimization of the docked complexes were performed, as well as optimization of the hydrogen bond network. The topology files of ligands were auto-generated by General AMBER Force Field (GAFF) with AM1BCC charges. A cubic simulation cell was constructed using the TIP3P solvation model with a periodic boundary condition (<xref ref-type="bibr" rid="B20">Kadaoluwa Pathirannahalage et al., 2021</xref>). The distance between the cubic box and the edge of the protein was set to 12.5&#xa0;&#xc5;, and the dimensions of the cubic box were 80 &#xd7; 80 &#xd7; 80&#xa0;&#xc5;. The simulated system was neutralized at a pH of 7.4, 310&#xa0;K, and 0.9% NaCl, representing physiological conditions (<xref ref-type="bibr" rid="B23">Kr et al., 2015</xref>). The particle mesh Ewald (PME) method was used to determine long-range electrostatic interactions with an 8.0&#xa0;&#xc5; cutoff radius (<xref ref-type="bibr" rid="B36">Simmonett and Brooks, 2021</xref>). A time step of 2.0 fs was chosen for the simulation. The primary energy minimization was carried out using steepest gradient algorithms with simulated annealing techniques (5,000 cycles). The RMSD, Rg, SASA, hydrogen bonding and MMPBSA binding free energy were evaluated using the simulated trajectories (<xref ref-type="bibr" rid="B2">Baildya et al., 2021</xref>; <xref ref-type="bibr" rid="B17">Islam et al., 2021</xref>). The simulation was conducted for 100&#xa0;ns, and the simulation trajectories were saved after every 100&#xa0;ps (<xref ref-type="bibr" rid="B29">Patil et al., 2021</xref>).</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and discussion</title>
<sec id="s3-1">
<title>3.1 GC-MS analysis</title>
<p>Plant-derived bioactive compounds have the potential to lower the complications associated with diabetes (<xref ref-type="bibr" rid="B39">Tran et al., 2020</xref>), and IR is a promising target for designing drugs for the curative treatment of diabetes mellitus. In this study, we identified a total of 17 phytochemicals present in <italic>A. pavonina</italic> leaf extract through GC-MS analysis (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="table" rid="T1">Table 1</xref>). Compound 3,7-Cyclodecadiene-1-methanol, .alpha.,.alpha.,4,8-tetramethyl was found to be the most abundant (29.15%) in this extract, followed by 2-(4-Ethenyl-4-methyl-3-prop-1-en-2-ylcyclohexyl)propan-2-ol (18.29%) and 2-Naphthalenemethanol, decahydro-.alpha.,alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha.,8a.beta.)] (14.15%) (<xref ref-type="table" rid="T1">Table 1</xref>). On the other hand, sabinene (27.9%) was the major compound of <italic>A. pavonina</italic> leaf oil, followed by D-limonene (14.79%), as detected through GC-MS analysis (<xref ref-type="bibr" rid="B10">El-Shazly et al., 2020</xref>). Although there was a significant difference in the concentrations of the compounds, some of the compounds were present at very low concentrations (&#x3c;1%) in this leaf extract (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Chromatography of the chemical compounds found in methanolic leaf extract of <italic>Adenanthera pavonina</italic> by GC-MS analysis.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g002.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Quantitative result for methanolic leaf extract of <italic>Adenanthera pavonina</italic>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">ID</th>
<th align="left">Name</th>
<th align="left">RT</th>
<th align="left">Area</th>
<th align="left">m/z</th>
<th align="left">Con.(%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">1H-3a,7-Methanoazulene, octahydro-1,4,9,9-tetramethyl</td>
<td align="left">15.47</td>
<td align="left">8,980</td>
<td align="left">55.00</td>
<td align="left">2.99</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">2,4,4,7a-Tetramethyl-1-(3-oxobutyl)octahydro-1H-indene-2-carboxylic acid</td>
<td align="left">17.38</td>
<td align="left">2076</td>
<td align="left">82.00</td>
<td align="left">0.69</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">5-Azulenemethanol, 1,2,3,3a,4,5,6,7-octahydro-.alpha.,.alpha.,3,8-tetramethyl-, [3S-(3.alpha.,3a.beta.,5.alpha.)]</td>
<td align="left">19.86</td>
<td align="left">33,445</td>
<td align="left">59.00</td>
<td align="left">11.16</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">Cyclohexanemethanol, 4-ethenyl-.alpha.,.alpha.,4-trimethyl-3-(1-methylethenyl)-, [1R-(1.alpha.,3.alpha.,4.beta.)]</td>
<td align="left">20.19</td>
<td align="left">5,617</td>
<td align="left">59.00</td>
<td align="left">1.87</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">3,7-Cyclodecadiene-1-methanol, .alpha.,.alpha.,4,8-tetramethyl</td>
<td align="left">20.35</td>
<td align="left">87,313</td>
<td align="left">59.00</td>
<td align="left">29.15</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Terpineol</td>
<td align="left">20.44</td>
<td align="left">2,555</td>
<td align="left">59.00</td>
<td align="left">0.85</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">2-Naphthalenemethanol, decahydro-.alpha.,.alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha.,8a.beta.)]</td>
<td align="left">20.67</td>
<td align="left">42,382</td>
<td align="left">59.00</td>
<td align="left">14.15</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">2-(4-Ethenyl-4-methyl-3-prop-1-en-2-ylcyclohexyl)propan-2-ol</td>
<td align="left">20.89</td>
<td align="left">54,788</td>
<td align="left">59.00</td>
<td align="left">18.29</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">Benzenepropanol, .alpha.,.alpha.-dimethyl-</td>
<td align="left">21.49</td>
<td align="left">11,013</td>
<td align="left">59.00</td>
<td align="left">3.67</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">Diazoprogesterone</td>
<td align="left">22.16</td>
<td align="left">3,300</td>
<td align="left">55.00</td>
<td align="left">1.11</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Pregnenolone carbonitrile</td>
<td align="left">22.30</td>
<td align="left">2,385</td>
<td align="left">91.00</td>
<td align="left">0.79</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Cyclopentaneundecanoic acid, methyl ester</td>
<td align="left">23.03</td>
<td align="left">3,167</td>
<td align="left">74.00</td>
<td align="left">1.05</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">Oxacyclotetradeca-4,11-diyne</td>
<td align="left">23.28</td>
<td align="left">1952</td>
<td align="left">91.00</td>
<td align="left">0.65</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">Cyclopropane, 1-(2-methylene-3-butenyl)-1-(1-methylenepropyl)-</td>
<td align="left">23.58</td>
<td align="left">3,575</td>
<td align="left">91.00</td>
<td align="left">1.19</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">Caffeine</td>
<td align="left">26.09</td>
<td align="left">29,497</td>
<td align="left">67.00</td>
<td align="left">9.84</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">Cyclopentaneundecanoic acid, methyl ester</td>
<td align="left">28.19</td>
<td align="left">7,444</td>
<td align="left">74.00</td>
<td align="left">2.48</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">Picolinyl 7-tetradecenoate</td>
<td align="left">16.02</td>
<td align="left">3,100</td>
<td align="left">62.00</td>
<td align="left">0.58</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>RT , retention time, Con.(%) &#x3d; Concentration (%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-2">
<title>3.2 Molecular docking</title>
<p>The presence of a mutation in the 5hhw domain of the IR prevents glucose uptake and metabolism, resulting in DMT2 (<xref ref-type="bibr" rid="B6">Cignarelli et al., 2019</xref>; <xref ref-type="bibr" rid="B44">Zhang et al., 2022</xref>). In our current study, we evaluated the <italic>A. pavonina</italic> leaf extract-derived bioactive compounds through <italic>in silico</italic> approach by targeting 5hhw protein to find out potential therapeutic drug candidates for DMT2. Based on their binding energy and number of interacting amino acid with the target protein 5hhw we have selected 3 compounds from 17 compounds for further <italic>in silico</italic> analysis (<xref ref-type="sec" rid="s10">Supplementary Table S1</xref>). We used cis-(R)-7-(3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (CID: 67035535) as a reference ligand because it was complexed with the crystal structure of the insulin receptor kinase domain. In the docking study, the binding energy for compound diazoprogesterone (CID: 104633) was &#x2212;9.2&#xa0;kcal/mol compared to the reference ligand CID: 67035535 (&#x2212;10.5&#xa0;kcal/mol). This was followed by the compounds 2,4,4,7a-Tetramethyl-1-(3-oxobutyl)octahydro-1H-indene-2-carboxylic acid (CID: 536510) and 2-Naphthalenemethanol, decahydro-.alpha.,.alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha., 8a.beta.)] (CID: 6432456), which exhibited binding energies of &#x2212;6.9&#xa0;kcal/mol and &#x2212;6.6&#xa0;kcal/mol, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). The complex 5hhw &#x2b; CID: 104633 exhibited two hydrogen bonds at A:THR1181 (2.88&#xa0;&#xc5;) and A:GLY1179 (2.21&#xa0;&#xc5;) (<xref ref-type="fig" rid="F3">Figure 3A</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). Similarly, the complex 5hhw &#x2b; CID: 536510 was stabilized by three hydrogen bonds at A:GLU1186 (2.17&#xa0;&#xc5;), A:TYR1189 (1.99&#xa0;&#xc5;), and A:ASP1183 (2.27&#xa0;&#xc5;) (<xref ref-type="fig" rid="F3">Figure 3B</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). However, the interaction between 5hhw and compound CID: 6432456 did not reveal any hydrogen bond but rather five alkyl bonds in the A chain of the 5hhw protein (<xref ref-type="fig" rid="F3">Figure 3C</xref>; <xref ref-type="table" rid="T2">Table 2</xref>). In contrast, the interaction between 5hhw and reference ligand (CID: 67035535) exhibited three hydrogen bonds at A:LYS1057 (2.20&#xa0;&#xc5;), A:GLU1104 (2.48&#xa0;&#xc5;), and A:MET1106 (2.59&#xa0;&#xc5;). The binding of these compounds to 5hhw may activate the IR by auto-phosphorylation and phosphorylation of intracellular substrates, thus initiating the insulin pathway and facilitating glucose uptake by the cell.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Docking results of three phytochemicals of <italic>Adenanthera pavonina</italic> which showed the highest binding energy with 5hhw protein.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Complexes</th>
<th align="center">Binding energy (kcal/mol)</th>
<th align="center">Amino acid residues</th>
<th align="center">Bond types</th>
<th align="center">Distances (&#xc5;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="center">5hhw &#x2b; CID: 104633</td>
<td rowspan="5" align="center">&#x2212;9.2</td>
<td align="center">A:THR1181</td>
<td align="center">H</td>
<td align="center">2.88</td>
</tr>
<tr>
<td align="center">A:GLY1179</td>
<td align="center">H</td>
<td align="center">2.21</td>
</tr>
<tr>
<td align="center">A:ASP1177</td>
<td align="center">AC</td>
<td align="center">2.40</td>
</tr>
<tr>
<td align="center">A:ARG1182</td>
<td align="center">UPP</td>
<td align="center">3.84</td>
</tr>
<tr>
<td align="center">A:ARG1163</td>
<td align="center">A</td>
<td align="center">4.54</td>
</tr>
<tr>
<td rowspan="4" align="center">5hhw &#x2b; CID: 536510</td>
<td rowspan="4" align="center">&#x2212;6.9</td>
<td align="center">A:GLU1186</td>
<td align="center">H</td>
<td align="center">2.17</td>
</tr>
<tr>
<td align="center">A:TYR1189</td>
<td align="center">H</td>
<td align="center">1.99</td>
</tr>
<tr>
<td align="center">A:ASP1183</td>
<td align="center">H</td>
<td align="center">2.27</td>
</tr>
<tr>
<td align="center">A:VAL1037</td>
<td align="center">A</td>
<td align="center">4.29</td>
</tr>
<tr>
<td rowspan="6" align="center">5hhw &#x2b; CID: 6432456</td>
<td rowspan="6" align="center">&#x2212;6.6</td>
<td align="center">A:VAL1087</td>
<td align="center">A</td>
<td align="center">3.88</td>
</tr>
<tr>
<td align="center">A:ALA1055</td>
<td align="center">A</td>
<td align="center">4.69</td>
</tr>
<tr>
<td align="center">A:MET1166</td>
<td align="center">A</td>
<td align="center">4.22</td>
</tr>
<tr>
<td align="center">A:VAL1037</td>
<td align="center">A</td>
<td align="center">3.59</td>
</tr>
<tr>
<td align="center">A:MET1103</td>
<td align="center">A</td>
<td align="center">4.70</td>
</tr>
<tr>
<td align="center">A:LYS1057</td>
<td align="center">UDD</td>
<td align="center">2.62</td>
</tr>
<tr>
<td rowspan="13" align="center">5hhw &#x2b; CID: 67035535 (References ligand)</td>
<td rowspan="13" align="center">&#x2212;10.5</td>
<td align="center">A:LYS1057</td>
<td align="center">H</td>
<td align="center">2.20</td>
</tr>
<tr>
<td align="center">A:GLU1104</td>
<td align="center">H</td>
<td align="center">2.48</td>
</tr>
<tr>
<td align="center">A:MET1106</td>
<td align="center">H</td>
<td align="center">2.59</td>
</tr>
<tr>
<td align="center">A:LEU1029</td>
<td align="center">CH</td>
<td align="center">3.58</td>
</tr>
<tr>
<td align="center">A:ASP1110</td>
<td align="center">CH</td>
<td align="center">3.78</td>
</tr>
<tr>
<td align="center">A:ASP1177</td>
<td align="center">CH</td>
<td align="center">3.37</td>
</tr>
<tr>
<td align="center">A:ALA1055</td>
<td align="center">A</td>
<td align="center">5.23</td>
</tr>
<tr>
<td align="center">A:ALA1075</td>
<td align="center">A</td>
<td align="center">5.37</td>
</tr>
<tr>
<td align="center">A:VAL1087</td>
<td align="center">A</td>
<td align="center">5.25</td>
</tr>
<tr>
<td align="center">A:VAL1101</td>
<td align="center">A</td>
<td align="center">4.74</td>
</tr>
<tr>
<td align="center">A:VAL1037</td>
<td align="center">PiS</td>
<td align="center">4.88</td>
</tr>
<tr>
<td align="center">A:MET1166</td>
<td align="center">PiS</td>
<td align="center">3.93</td>
</tr>
<tr>
<td align="center">A:MET:1103</td>
<td align="center">PS</td>
<td align="center">3.57</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>H &#x3d; hydrogen bond, CH, carbon hydrogen bond; AC, attractive charge; UPP, Unfavorable positive-positive bond, A &#x3d; alkyl bond, UDD, Unfavorable donor-donor bond, PiS &#x3d; Pi-Sigma, PS, Pi-Sulfur bond.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Molecular docking between 5hhw protein and compounds from <italic>Adenanthera pavonina</italic>; and surface, pose and 2D view of complexes 5hhw &#x2b; CID: 104633 <bold>(A)</bold>, 5hhw &#x2b; CID: 536510 <bold>(B)</bold>, 5hhw &#x2b; CID: 6432456 <bold>(C)</bold> and reference molecule bound complex 5hhw &#x2b; CID: 67035535 <bold>(D)</bold> respectively.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g003.tif"/>
</fig>
<p>An <italic>in silico</italic> study has found that plant-derived polyphenols, such as flavonoids, can trigger the activation loop of IR, suggesting that they can be considered activators of IR (<xref ref-type="bibr" rid="B24">Lim et al., 2021</xref>). However, some <italic>in vitro</italic> and <italic>in vivo</italic> studies suggest that <italic>A. pavonina</italic>-derived phytochemicals possess antidiabetic activity (<xref ref-type="bibr" rid="B43">Wickramaratne et al., 2016</xref>; <xref ref-type="bibr" rid="B41">Vieira et al., 2018</xref>). The phytochemical galactomannans, isolated from <italic>A. pavonina</italic>, can reduce glycemia, total cholesterol, and triacylglycerol levels in streptozotocin-induced diabetic mice (<xref ref-type="bibr" rid="B41">Vieira et al., 2018</xref>). The methanolic leaf extract of <italic>A. pavonina</italic> significantly inhibits the alpha-amylase activity (IC<sub>50</sub> value 16.16 &#xb1; 2.23&#xa0;&#xb5;g/mL) (<xref ref-type="bibr" rid="B43">Wickramaratne et al., 2016</xref>). It has been found that the seed aqueous extract of <italic>A. pavonina</italic> can reduce the development of diabetic nephropathy in streptozotocin-induced diabetic mice (<xref ref-type="bibr" rid="B28">Pandhare et al., 2012</xref>).</p>
</sec>
<sec id="s3-3">
<title>3.3 ADMET analysis</title>
<p>The compounds screened through molecular docking were chosen for ADMET analysis to evaluate their biocompatibility, pharmacokinetics, and toxicity, and to identify the lead compound. According to Lipinski&#x2019;s rule, a lead compound should have certain properties, such as molecular weight &#x2264;500 da, hydrogen bond acceptor &#x2264;10, hydrogen bond donor &#x2264;5 and LogP value &#x2264; 5. At least two violations are considered according to this rule (<xref ref-type="bibr" rid="B1">Abbasi et al., 2019</xref>). In the present study, it was found that all compounds met Lipinski&#x2019;s rule (No violation). The bioavailability score of a compound determines its physiological activity (<xref ref-type="bibr" rid="B18">Jia et al., 2020</xref>). All three compounds were found to be physiologically active (&#x3e;0.00), and their bioavailability scores were the same (0.55) (<xref ref-type="table" rid="T3">Table 3</xref>). The water solubility profile showed that compound CID: 536510 (&#x2212;2.543) was water soluble, while compounds CID: 104633 (&#x2212;4.101) and CID: 6432456 (&#x2212;4.9) were moderately soluble according to the solubility scale, which is insoluble &#x3c; &#x2212;10 &#x3c; poorly &#x3c; &#x2212;6 &#x3c; moderately &#x3c; &#x2212;4 &#x3c; soluble &#x3c; &#x2212;2 &#x3c; very &#x3c;0 &#x3c; highly (<xref ref-type="bibr" rid="B42">Wang et al., 2021</xref>). The blood-brain barrier (BBB) permeability of a drug is crucial for its ability to reach the brain (<xref ref-type="bibr" rid="B8">Daina and Zoete, 2016</xref>). The BBB and CNS permeability of compounds CID: 104633, CID: 536510, and CID: 6432456 were 0.084 and &#x2212;1.843, 0.361 and &#x2212;1.104, and 0.634 and &#x2212;1.858, respectively. Furthermore, all screened compounds showed positive (No) results in the human ether-a-go-go (hERG) I inhibitor test, and no toxicity was found in terms of the AMES test, however, compound CID: 536510 was found as hepatotoxic (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Pharmacological and toxicity predictions of the selected compounds using pkCSM and SwissADME tools where every compound had almost favorable drug-likeness properties.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Parameters</th>
<th align="center">CID: 104633</th>
<th align="center">CID: 536510</th>
<th align="center">CID: 6432456</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Molecular weight</td>
<td align="center">340.46</td>
<td align="center">260.42</td>
<td align="center">222.308</td>
</tr>
<tr>
<td align="left">Molecular formula</td>
<td align="center">C<sub>21</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub>
</td>
<td align="center">C<sub>17</sub>H<sub>28</sub>N<sub>2</sub>
</td>
<td align="center">C<sub>15</sub>H<sub>26</sub>O</td>
</tr>
<tr>
<td align="left">Hydrogen bond donor</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">Hydrogen bond acceptor</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">Rotatable bonds</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">LogP</td>
<td align="center">4.0042</td>
<td align="center">2.9244</td>
<td align="center">3.92</td>
</tr>
<tr>
<td align="left">Surface Area</td>
<td align="center">149.230</td>
<td align="center">117.540</td>
<td align="center">99.941</td>
</tr>
<tr>
<td align="left">Lipinski</td>
<td align="center">Yes; 0 violation</td>
<td align="center">Yes; 0 violation</td>
<td align="center">Yes; 0 violation</td>
</tr>
<tr>
<td align="left">Bioavailability score</td>
<td align="center">0.55</td>
<td align="center">0.55</td>
<td align="center">0.55</td>
</tr>
<tr>
<td align="left">Water solubility</td>
<td align="center">&#x2212;4.101</td>
<td align="center">&#x2212;2.543</td>
<td align="center">&#x2212;4.9</td>
</tr>
<tr>
<td align="left">Human intestinal absorption</td>
<td align="center">97.088</td>
<td align="center">92.973</td>
<td align="center">94.296</td>
</tr>
<tr>
<td align="left">Blood brain barrier</td>
<td align="center">0.084</td>
<td align="center">0.361</td>
<td align="center">0.634</td>
</tr>
<tr>
<td align="left">CNS permeability</td>
<td align="center">&#x2212;1.843</td>
<td align="center">&#x2212;1.104</td>
<td align="center">&#x2212;1.858</td>
</tr>
<tr>
<td align="left">P-Glycoprotein 1 inhibitor</td>
<td align="center">Yes</td>
<td align="center">No</td>
<td align="center">No</td>
</tr>
<tr>
<td align="left">CaCo2 Permeability</td>
<td align="center">0.662</td>
<td align="center">1.497</td>
<td align="center">1.508</td>
</tr>
<tr>
<td align="left">CYP2D6 substrate</td>
<td align="center">No</td>
<td align="center">No</td>
<td align="center">No</td>
</tr>
<tr>
<td align="left">Oral Rat Acute Toxicity (LD50)</td>
<td align="center">2.717</td>
<td align="center">2.903</td>
<td align="center">1.727</td>
</tr>
<tr>
<td align="left">AMES Toxicity</td>
<td align="center">No</td>
<td align="center">No</td>
<td align="center">No</td>
</tr>
<tr>
<td align="left">Hepatotoxicity</td>
<td align="center">No</td>
<td align="center">Yes</td>
<td align="center">No</td>
</tr>
<tr>
<td align="left">hERG I Inhibitor</td>
<td align="center">No</td>
<td align="center">No</td>
<td align="center">No</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-4">
<title>3.4 Molecular dynamics</title>
<p>Molecular dynamics simulations were conducted to assess the stability of the hit complexes during the 100&#xa0;ns simulation period. The RMSD value was utilized as the standard measure of structural distance between coordinates (<xref ref-type="bibr" rid="B40">Vel&#xe1;zquez-Libera et al., 2020</xref>). The three best hit compounds were selected for molecular dynamics simulations to analyze their stability and identify potential inhibitors in a time-dependent manner for 100&#xa0;ns Five parameters, including the root mean square deviation (RMSD), radius of gyration (Rg), solvent-accessible surface area (SASA), hydrogen bonds and MMPBSA binding free energy of the hit complexes were investigated.</p>
<p>In this study, all four complexes demonstrated satisfactory RMSD, although there was some fluctuation in the data at the very beginning of the simulation period (<xref ref-type="fig" rid="F4">Figure 4A</xref>). The initial RMSD values of the four complexes were below 1&#xa0;&#xc5;, but after a few ns, the RMSD values of all complexes increased. Complex C2 (5hhw &#x2b; CID: 536510) exhibited more fluctuation than complexes C1 (5hhw &#x2b; CID: 104633), C3 (5hhw &#x2b; CID: 6432456), reference ligand-bound complex R (5hhw &#x2b; CID: 67035535), and Apo protein after 20&#xa0;ns. This might be due to the conformational variability of the C2 complex (<xref ref-type="bibr" rid="B33">Saha et al., 2023</xref>). After this period, both C1 and C2 maintained a stable RMSD value for the rest of the simulation period, whereas R and Apo maintained stability with C3 until 80&#xa0;ns and then R showed a downward trend with a slight increase at the end. However, the C3 complex exhibited an increased RMSD value until 60&#xa0;ns, and then finally followed the stable trend with the other complexes (<xref ref-type="fig" rid="F4">Figure 4A</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>The molecular dynamics simulations of the docked C1, C2, C3, R and Apo complexes, where <bold>(A)</bold>, <bold>(B)</bold>, <bold>(C)</bold> and <bold>(D)</bold> indicate RMSD, Rg, SASA and hydrogen bonds respectively.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g004.tif"/>
</fig>
<p>During the 20&#xa0;ns of the simulation period, the Rg values of C2, C3, R and Apo protein showed an increasing trend, while C1 exhibited a decreasing movement. From 20&#xa0;ns to 75&#xa0;ns, all complexes demonstrated a stable profile. Afterward, C1 and C2 showed an upward movement, while C3, R and Apo showed a downward trend. However, at the end of the simulation period, they converged at nearly the same point (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The Rg profiles of C3, R, and Apo maintained almost the same trend, while C1 and C2 exhibited slight fluctuations during the simulation period due to the folding and changes in the conformation of the complexes (<xref ref-type="bibr" rid="B32">Rodrigues et al., 2018</xref>). The SASA profiles of C1, C2, C3, R and Apo were satisfactory, and they exhibited similar trends and stable profiles throughout the entire simulation period (<xref ref-type="fig" rid="F4">Figure 4C</xref>). Similarly, the hydrogen bonding in these complexes also followed the same trend as the SASA profile throughout the simulation time (<xref ref-type="fig" rid="F4">Figure 4D</xref>).</p>
<p>Molecular Mechanics/Poisson-Boltzmann Surface Area (MMPBSA) was used to calculate the binding free energy of protein-ligand interactions (<xref ref-type="bibr" rid="B25">Lyndem et al., 2023</xref>). The MMPBSA binding free energy of all complexes during the last 20&#xa0;ns simulation period is shown in <xref ref-type="fig" rid="F5">Figure 5A</xref>. The average MMPBSA binding free energies of complexes C1, C2, C3, and R were &#x2212;54.69 &#xb1; 2.40, &#x2212;43.53 &#xb1; 0.28, &#x2212;31.64 &#xb1; 0.88 and &#x2212;22.40 &#xb1; 2.72&#xa0;kJ/mol, respectively (<xref ref-type="fig" rid="F5">Figure 5B</xref>). The negative MMPBSA binding free energy indicates the stability of the C1, C2, C3 and R complexes (<xref ref-type="fig" rid="F5">Figure 5A</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>MMPBSA binding free energies of complexes C1, C2, C3 and R; where <bold>(A)</bold> displays the MMPBSA binding free energy at the 20&#xa0;ns simulation period, and <bold>(B)</bold> shows the average MMPBSA binding free energy.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g005.tif"/>
</fig>
<p>Snapshots of molecular dynamics simulations were extracted at 0, 20, 40, 60, 80 and 100&#xa0;ns to confirm the binding of ligands to the receptor. The findings indicate that the ligands remained bound to the receptor throughout the simulation period (<xref ref-type="fig" rid="F6">Figure 6</xref>). Overall, the results of the molecular dynamics simulations suggest that CID: 104633, CID: 536510 and CID: 6432456 could serve as lead compounds.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Snapshots of the molecular dynamics simulations for the complexes C1, C2, C3 and R at 0, 20, 40, 60, 80 and 100&#xa0;ns?</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>3.5 Protein-ligand interactions after simulation</title>
<p>In <xref ref-type="fig" rid="F7">Figure 7</xref>, the interaction between the protein and ligand after a 100&#xa0;ns simulation period is depicted (<xref ref-type="bibr" rid="B34">Saha and Nath Jha, 2023</xref>). The results revealed that the number of interactions between the complexes 5hhw &#x2b; CID: 104633, 5hhw &#x2b; CID: 536510, 5hhw &#x2b; CID: 6432456 and 5hhw &#x2b; CID: 67035535 was 4, 3, 4 and 9 respectively (<xref ref-type="table" rid="T4">Table 4</xref>), which closely resembled the docking interactions presented in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The 2D view of protein-ligand interactions after 100&#xa0;ns simulation period where <bold>(A)</bold> 5hhw &#x2b; CID: 104633, <bold>(B)</bold> 5hhw &#x2b; CID: 536510, <bold>(C)</bold> 5hhw &#x2b; CID: 6432456 and <bold>(D)</bold> 5hhw &#x2b; CID: 67035535.</p>
</caption>
<graphic xlink:href="fmolb-10-1278701-g007.tif"/>
</fig>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Interactions between protein and ligand after 100 ns simulation period.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Complexes</th>
<th align="left">Amino acid residues</th>
<th align="left">Bond types</th>
<th align="left">Distances (&#xc5;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="left">5hhw &#x2b; CID: 104633</td>
<td align="left">A:ARG1163</td>
<td align="left">H</td>
<td align="left">4.54</td>
</tr>
<tr>
<td align="left">A:GLY1179</td>
<td align="left">H</td>
<td align="left">2.21</td>
</tr>
<tr>
<td align="left">A:THR1181</td>
<td align="left">H</td>
<td align="left">2.88</td>
</tr>
<tr>
<td align="left">A:ASP1177</td>
<td align="left">AC</td>
<td align="left">3.26</td>
</tr>
<tr>
<td rowspan="3" align="left">5hhw &#x2b; CID: 536510</td>
<td align="left">A:ASP1183</td>
<td align="left">H</td>
<td align="left">2.17</td>
</tr>
<tr>
<td align="left">A:GLU1186</td>
<td align="left">H</td>
<td align="left">2.25</td>
</tr>
<tr>
<td align="left">A:TYR1189</td>
<td align="left">H</td>
<td align="left">2.03</td>
</tr>
<tr>
<td rowspan="4" align="left">5hhw &#x2b; CID: 6432456</td>
<td align="left">A:VAL1037</td>
<td align="left">A</td>
<td align="left">5.37</td>
</tr>
<tr>
<td align="left">A:ALA1055</td>
<td align="left">A</td>
<td align="left">4.98</td>
</tr>
<tr>
<td align="left">A:VAL1087</td>
<td align="left">A</td>
<td align="left">5.12</td>
</tr>
<tr>
<td align="left">A:MET1166</td>
<td align="left">A</td>
<td align="left">4.20</td>
</tr>
<tr>
<td rowspan="9" align="left">5hhw &#x2b; CID: 67035535 (References ligand)</td>
<td align="left">A:LYS1057</td>
<td align="left">H</td>
<td align="left">2.20</td>
</tr>
<tr>
<td align="left">A:MET1106</td>
<td align="left">H</td>
<td align="left">2.59</td>
</tr>
<tr>
<td align="left">A:ASP1110</td>
<td align="left">CH</td>
<td align="left">3.78</td>
</tr>
<tr>
<td align="left">A:ASP1177</td>
<td align="left">CH</td>
<td align="left">3.37</td>
</tr>
<tr>
<td align="left">A:ALA1055</td>
<td align="left">A</td>
<td align="left">3.96</td>
</tr>
<tr>
<td align="left">A:VAL1087</td>
<td align="left">A</td>
<td align="left">5.25</td>
</tr>
<tr>
<td align="left">A:VAL1101</td>
<td align="left">A</td>
<td align="left">4.74</td>
</tr>
<tr>
<td align="left">A:MET1166</td>
<td align="left">PiS</td>
<td align="left">3.66</td>
</tr>
<tr>
<td align="left">A:MET:1103</td>
<td align="left">PS</td>
<td align="left">3.57</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>The phytochemicals Diazoprogesterone, 2,4,4,7a-Tetramethyl-1-(3-oxobutyl)octahydro-1H-indene-2-carboxylic acid, and 2-Naphthalenemethanol, decahydro-.alpha.,.alpha.,4a-trimethyl-8-methylene-, [2R-(2.alpha.,4a.alpha.,8a.beta.)], derived from <italic>A. pavonina</italic>, showed potential activity in molecular docking studies with the 5hhw protein however their activity is comparatively lower compared to the control, and exhibited positive results in ADMET analysis, indicating favorable pharmacokinetic and safety properties. Molecular dynamics simulations further supported their strong binding interactions with the 5hhw receptor over time. These findings suggest that these phytochemicals hold promise as potential activators of 5hhw protein, making them possible candidates for the development of novel therapies for diabetes mellitus. Nevertheless, to ascertain their therapeutic potential fully, additional <italic>in vitro</italic> and <italic>in vivo</italic> investigations are essential, followed by rigorous clinical trials to determine their safety, efficacy, and appropriate dosages for human use. The use of these phytochemicals as activators of 5hhw protein could represent a significant step towards finding new and effective treatments for diabetes mellitus, but comprehensive research and validation are critical before their clinical application.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>MSR: Conceptualization, Investigation, Methodology, Data curation, Formal Analysis, Visualization, Writing&#x2013;original draft. MEH: Conceptualization, Investigation, Methodology, Data curation, Formal Analysis, Visualization, Writing&#x2013;review and editing. MOF: Formal Analysis, Resources, Software, Writing&#x2013;review and editing. MK: Resources, Investigation, Writing&#x2013;review and editing. MAI: Resources, Investigation, Writing&#x2013;review and editing. UKA: Resources, Investigation, Writing&#x2013;review and editing. YBJ: Project administration, Validation, Writing&#x2013;review and editing, Funding acquisition. HN: Project administration, Validation, Writing&#x2013;review and editing, Funding acquisition. AM: Project administration, Validation, Writing&#x2013;review and editing, Funding acquisition. MB: Project administration, Validation, Writing&#x2013;review and editing, Funding acquisition. RZ: Supervision, Investigation, Formal Analysis, Resources, Project administration, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article. This research work was funded by the Ministry of Science and Technology, People&#x2019;s Republic of Bangladesh (No. 39.00.0000.012.002.05.20-04). This work is financially supported by the Researchers Supporting Project number RSP2024R457, King Saud University, Riyadh, Saudi Arabia.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2023.1278701/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2023.1278701/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbasi</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Raza</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S. Z.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>S. A. A.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>S.-Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Synthesis of novel N-(1, 3-thiazol-2-yl) benzamide clubbed oxadiazole scaffolds: urease inhibition, Lipinski rule and molecular docking analyses</article-title>. <source>Bioorg. Chem.</source> <volume>83</volume>, <fpage>63</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2018.10.018</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baildya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Screening of potential drug from Azadirachta Indica (Neem) extracts for SARS-CoV-2: an insight from molecular docking and MD-simulation studies</article-title>. <source>J. Mol. Struct.</source> <volume>1227</volume>, <fpage>129390</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2020.129390</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis</article-title>. <source>J. Matern. Neonatal Med.</source> <volume>34</volume> (<issue>16</issue>), <fpage>2741</fpage>&#x2013;<lpage>2753</lpage>. <pub-id pub-id-type="doi">10.1080/14767058.2019.1670804</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brierley</surname>
<given-names>G. V.</given-names>
</name>
<name>
<surname>Siddle</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Semple</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Evaluation of anti-insulin receptor antibodies as potential novel therapies for human insulin receptoropathy using cell culture models</article-title>. <source>Diabetologia</source> <volume>61</volume>, <fpage>1662</fpage>&#x2013;<lpage>1675</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-018-4606-2</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choudhary</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Bora</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A novel small molecule A2A adenosine receptor agonist, indirubin-3&#x2032;-monoxime, alleviates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes</article-title>. <source>Biochem. J.</source> <volume>476</volume> (<issue>16</issue>), <fpage>2371</fpage>&#x2013;<lpage>2391</lpage>. <pub-id pub-id-type="doi">10.1042/BCJ20190251</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cignarelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Genchi</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Perrini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Natalicchio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laviola</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Giorgino</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Insulin and insulin receptors in adipose tissue development</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>3</issue>), <fpage>759</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20030759</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michielin</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>42717</fpage>. <pub-id pub-id-type="doi">10.1038/srep42717</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zoete</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules</article-title>. <source>ChemMedChem</source> <volume>11</volume> (<issue>11</issue>), <fpage>1117</fpage>&#x2013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201600182</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dallakyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Small-molecule library screening by docking with PyRx</article-title>. <source>Methods Mol. Biol.</source> <volume>1263</volume>, <fpage>243</fpage>&#x2013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Shazly</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Elsayed</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Elgindi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Singab</surname>
<given-names>A.-N.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Characterization of essential oils of the leaves and fruits of Adenanthera pavonina L. By GC/MS</article-title>. <source>Arch. Pharm. Sci. Ain Shams Univ.</source> <volume>4</volume> (<issue>1</issue>), <fpage>63</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.21608/aps.2020.2001.1027</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rahmani</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Dev</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Diabetes: perspective and challenges in modern era</article-title>. <source>Gene Rep.</source> <volume>20</volume>, <fpage>100759</fpage>. <pub-id pub-id-type="doi">10.1016/j.genrep.2020.100759</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haeusler</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>McGraw</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Accili</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Biochemical and cellular properties of insulin receptor signalling</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>19</volume> (<issue>1</issue>), <fpage>31</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.89</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Insulin receptor endocytosis in the pathophysiology of insulin resistance</article-title>. <source>Exp. Mol. Med.</source> <volume>52</volume> (<issue>6</issue>), <fpage>911</fpage>&#x2013;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-020-0456-3</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>V. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T.-S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A fast and high-quality charge model for the next generation general AMBER force field</article-title>. <source>J. Chem. Phys.</source> <volume>153</volume> (<issue>11</issue>), <fpage>114502</fpage>. <pub-id pub-id-type="doi">10.1063/5.0019056</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hills</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khunti</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yajnik</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Jayawardena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>C. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Epidemiology and determinants of type 2 diabetes in south asia</article-title>. <source>lancet Diabetes Endocrinol.</source> <volume>6</volume> (<issue>12</issue>), <fpage>966</fpage>&#x2013;<lpage>978</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(18)30204-3</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iglay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hannachi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Joseph Howie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>S. S.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Prevalence and Co-prevalence of comorbidities among patients with type 2 diabetes mellitus</article-title>. <source>Curr. Med. Res. Opin.</source> <volume>32</volume> (<issue>7</issue>), <fpage>1243</fpage>&#x2013;<lpage>1252</lpage>. <pub-id pub-id-type="doi">10.1185/03007995.2016.1168291</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parves</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Mamun</surname>
<given-names>A.Al</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>39</volume> (<issue>9</issue>), <fpage>3213</fpage>&#x2013;<lpage>3224</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>G.-F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.-F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>A drug-likeness toolbox facilitates ADMET study in drug Discovery</article-title>. <source>Drug Discov. Today</source> <volume>25</volume> (<issue>1</issue>), <fpage>248</fpage>&#x2013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2019.10.014</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Genetic analysis and clinical features of a pedigree affected with hereditary coagulation factor - deficiency caused by compound heterozygotic mutations</article-title>. <source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source> <volume>36</volume> (<issue>10</issue>), <fpage>1006</fpage>&#x2013;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.issn.1003-9406.2019.10.014</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadaoluwa Pathirannahalage</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Meftahi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elbourne</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>A. C. G.</given-names>
</name>
<name>
<surname>McConville</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Padua</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Systematic comparison of the structural and dynamic properties of commonly used water models for molecular dynamics simulations</article-title>. <source>J. Chem. Inf. Model.</source> <volume>61</volume> (<issue>9</issue>), <fpage>4521</fpage>&#x2013;<lpage>4536</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00794</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanthal</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Satyavathi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bhojaraju</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>GC-MS analysis of bio-active compounds in methanolic extract of lactuca runcinata DC</article-title>. <source>Pharmacogn. Res.</source> <volume>6</volume> (<issue>1</issue>), <fpage>58</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.4103/0974-8490.122919</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karadag</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Ozlu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lavery</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cutaneous manifestations of diabetes mellitus and the metabolic syndrome</article-title>. <source>Clin. Dermatol.</source> <volume>36</volume> (<issue>1</issue>), <fpage>89</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.clindermatol.2017.09.015</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krieger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vriend</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>New ways to boost molecular dynamics simulations</article-title>. <source>J. Comput. Chem.</source> <volume>36</volume> (<issue>13</issue>), <fpage>996</fpage>&#x2013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.23899</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C.-I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K. H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Antidiabetic flavonoids from fruits of morus alba promoting insulin-stimulated glucose uptake via akt and AMP-activated protein kinase activation in 3T3-L1 adipocytes</article-title>. <source>Pharmaceutics</source> <volume>13</volume> (<issue>4</issue>), <fpage>526</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13040526</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyndem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hazarika</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bhatta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>
<italic>In vitro</italic> interactions of esculin and esculetin with bovine hemoglobin alter its structure and inhibit aggregation: insights from spectroscopic and computational studies</article-title>. <source>New J. Chem.</source> <volume>47</volume> (<issue>30</issue>), <fpage>14447</fpage>&#x2013;<lpage>14468</lpage>. <pub-id pub-id-type="doi">10.1039/d3nj02273k</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marselli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bugliani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boggi</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Filipponi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Ultrastructural alterations of pancreatic beta cells in human diabetes mellitus</article-title>. <source>Diabetes. Metab. Res. Rev.</source> <volume>33</volume> (<issue>6</issue>), <fpage>e2894</fpage>. <pub-id pub-id-type="doi">10.1002/dmrr.2894</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nolan</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Prentki</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift</article-title>. <source>Diabetes Vasc. Dis. Res.</source> <volume>16</volume> (<issue>2</issue>), <fpage>118</fpage>&#x2013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1177/1479164119827611</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandhare</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sangameswaran</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Extract of <italic>Adenanthera pavonina</italic> L. seed reduces development of diabetic nephropathy in streptozotocin-induced diabetic rats</article-title>. <source>Avicenna J. Phytomedicine</source> <volume>2</volume> (<issue>4</issue>), <fpage>233</fpage>&#x2013;<lpage>242</lpage>.</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patil</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Maruthi</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Bajpe</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Vyshali</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Sushmitha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Akhila</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)</article-title>. <source>Bioinformation</source> <volume>17</volume> (<issue>11</issue>), <fpage>932</fpage>&#x2013;<lpage>939</lpage>. <pub-id pub-id-type="doi">10.6026/97320630017932</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pires</surname>
<given-names>D. E. V.</given-names>
</name>
<name>
<surname>Blundell</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Ascher</surname>
<given-names>D. B.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures</article-title>. <source>J. Med. Chem.</source> <volume>58</volume> (<issue>9</issue>), <fpage>4066</fpage>&#x2013;<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riyaphan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>D.-C.</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>C.-F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>
<italic>In silico</italic> approaches to identify polyphenol compounds as &#x3b1;-glucosidase and &#x3b1;-amylase inhibitors against type-II diabetes</article-title>. <source>Biomolecules</source> <volume>11</volume> (<issue>12</issue>), <fpage>1877</fpage>. <pub-id pub-id-type="doi">10.3390/biom11121877</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C. F. R. de</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>L. H. O.</given-names>
</name>
<name>
<surname>Neto</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Boleti</surname>
<given-names>A. P. A.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>E. L. dos</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Adevonin, a novel synthetic antimicrobial peptide designed from the Adenanthera pavonina trypsin inhibitor (ApTI) sequence</article-title>. <source>Pathog. Glob. Health</source> <volume>112</volume> (<issue>8</issue>), <fpage>438</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1080/20477724.2018.1559489</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Borah</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>A. N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Molecular scaffold recognition of drug molecules against essential genes of leishmania donovani using biocomputing approach</article-title>. <source>South Afr. J. Bot.</source> <volume>162</volume>, <fpage>52</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2023.08.067</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nath Jha</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Computational multi-target approach to target essential enzymes of leishmania donovani using comparative molecular dynamic simulations and MMPBSA analysis</article-title>. <source>Phytochem. Anal.</source> <volume>34</volume>, <fpage>842</fpage>&#x2013;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1002/pca.3213</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wahi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Soni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bansiwal</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Transcriptome profiling reveals association of peripheral adipose tissue pathology with type-2 diabetes in asian Indians</article-title>. <source>Adipocyte</source> <volume>8</volume> (<issue>1</issue>), <fpage>125</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1080/21623945.2019.1595269</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simmonett</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A compression strategy for particle mesh Ewald theory</article-title>. <source>J. Chem. Phys.</source> <volume>154</volume> (<issue>5</issue>), <fpage>054112</fpage>. <pub-id pub-id-type="doi">10.1063/5.0040966</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Kucukkal</surname>
<given-names>T. G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Computational chemistry activities with Avogadro and ORCA</article-title>. <source>J. Chem. Educ.</source> <volume>98</volume> (<issue>4</issue>), <fpage>1335</fpage>&#x2013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jchemed.0c00959</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stauffer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cowan-Jacob</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Scheufler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Furet</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo [2, 3-d] pyrimidine series of IGF-1R inhibitors</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>26</volume> (<issue>8</issue>), <fpage>2065</fpage>&#x2013;<lpage>2067</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.02.074</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tran</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug Discovery</article-title>. <source>Biol. (Basel)</source> <volume>9</volume> (<issue>9</issue>), <fpage>252</fpage>. <pub-id pub-id-type="doi">10.3390/biology9090252</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vel&#xe1;zquez-Libera</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Dur&#xe1;n-Verdugo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vald&#xe9;s-Jim&#xe9;nez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>N&#xfa;&#xf1;ez-Vivanco</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Caballero</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>LigRMSD: a web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking</article-title>. <source>Bioinformatics</source> <volume>36</volume> (<issue>9</issue>), <fpage>2912</fpage>&#x2013;<lpage>2914</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa018</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira</surname>
<given-names>I. G. P.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>F. N. P.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Paim</surname>
<given-names>R. T. T.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>S. R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Antidiabetic effects of galactomannans from Adenanthera pavonina L. In streptozotocin-induced diabetic mice</article-title>. <source>Asian pac. J. Trop. Med.</source> <volume>11</volume> (<issue>2</issue>), <fpage>116</fpage>. <pub-id pub-id-type="doi">10.4103/1995-7645.225018</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Large-scale one-pot synthesis of water-soluble and biocompatible upconversion nanoparticles for dual-modal imaging</article-title>. <source>Colloids Surfaces B Biointerfaces</source> <volume>198</volume>, <fpage>111480</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111480</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wickramaratne</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Punchihewa</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Wickramaratne</surname>
<given-names>D. B. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>
<italic>In-vitro</italic> alpha amylase inhibitory activity of the leaf extracts of Adenanthera pavonina</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>16</volume> (<issue>1</issue>), <fpage>466</fpage>&#x2013;<lpage>475</lpage>. <pub-id pub-id-type="doi">10.1186/s12906-016-1452-y</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The insulin receptor: an important target for the development of novel medicines and pesticides</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>14</issue>), <fpage>7793</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23147793</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>